Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Digestive System Diseases

Gland and Hormone Related Diseases

Heart and Blood Diseases

Symptoms and General Pathology

Nervous System Diseases

Musculoskeletal Diseases

Rare Diseases

Breast Neoplasms

Prostatic Neoplasms

Pancreatic Neoplasms

Carcinoma, Renal Cell

Arrhythmias, Cardiac

Liver Neoplasms

Head and Neck Neoplasms

Brain Neoplasms

Kidney Neoplasms

Spinal Neoplasms

Heart Diseases

Urologic Neoplasms

Urogenital Neoplasms

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Kidney Diseases

Urologic Diseases

Male Urogenital Diseases

Central Nervous System Neoplasms

Nervous System Neoplasms

Brain Diseases

Central Nervous System Diseases

Genital Neoplasms, Male

Genital Diseases

Genital Diseases, Male

Prostatic Diseases

Bone Neoplasms

Bone Diseases

Spinal Diseases

Pancreatic Cancer

Renal Cell Carcinoma

Hematinics

All Drugs and Chemicals

Liver Extracts

Patients having radiation therapy for treatment of brain cancer.

Patients having radiation therapy for treatment of breast cancer.

Patients having radiation therapy for treatment of head and neck cancer.

Patients having radiation therapy for treatment of kidney cancer.

Patients having radiation therapy for treatment of liver cancer.

Patients having radiation therapy for treatment of pancreatic cancer.

Patients having radiation therapy for treatment of prostate cancer.

Patients having radiation therapy for treatment of spinal cancer.

Patients having radiation therapy for treatment of cardiac arrhythmia

Shona Silvester

Natalie Plant

Principal Investigator

Paul Keall

This study will develop a whole-of-body markerless tracking method for measuring the motion of the tumour and surrounding organs during radiation therapy to enable real-time image guidance.

Routinely acquired patient data will be used to improve the training, testing and accuracy of a whole-of-body markerless tracking method. When the markerless tracking method is sufficiently advanced, according to the PI of each of the data collection sites, the markerless tracking method will be run in parallel to, but not intervening with, patient treatments during data acquisition.

This observational study will access routinely acquired radiation therapy treatment data from 300 patients including brain, breast, head and neck, kidney, liver, pancreas, prostate, spine and cardiac anatomic sites. At least 30 patients will be recruited from each anatomic site to enable sufficient data for the markerless tracking method training, testing and validation. The clinical data will be used to develop, train, test and validate a markerless target tracking method.

After the treatment, the ground truth and the variability in the ground truth will be computed. The patient images, the markerless tracking results, the ground truth and the variability will be uploaded to an in-house developed clinical trial learning system. Uploading additional data to the learning system automatically triggers the model building of the deep learning system. In this manner, the learning system gets both more accurate and more robust with each patient accrued. As the patient data accrues, the primary hypothesis of targeting accuracy can be tested.

The developed markerless tracking software will be applied by study personnel to the treatment imaging data for each anatomic site using five-fold cross-validation where 80% of the data is used for training and the remaining unseen 20% of the data is used for testing. Target positions produced by the markerless tracking will be compared with a 'ground truth'.

LEARN: Learning Environment for Artificial Intelligence in Radiotherapy New Technology

After study completion, de-identified (non-coded, non-re-identifiable) data will be available to researchers for further scientific research. Information about data sharing will be provided to study participants in the Patient Information Sheet.

Proportion of markerless tracking within 5 mm of the ground truth for each of nine anatomical sites (cohorts)

Proportion of radiation therapists considering the markerless tracking system acceptable using a survey

Spots Global Cancer Trial Database for spinal neoplasm